Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.

Journal of neuro-oncology - 1 Jan 2000

Mintz Akiva, Gibo Denise M, Madhankumar A B, Debinski Waldemar

Abstract excerpt

A restricted receptor for interleukin 13 (IL-13R alpha2) is over-expressed in high-grade astrocytoma (HGA), but not in normal organs. In order to design and examine new anti-HGA therapies, which are molecularly directed against IL-13R alpha2, we established an IL-13R alpha2-expressing syngeneic i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytotoxins
Share to Exotoxins
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunization, Passive

Share to Immunotoxins

Share to Interleukin-13

Share to Pseudomonas

Share to Receptors, Interleukin

Source

Identifiers

PMID: 12952292
DOI: 10.1007/BF02700026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-12952292-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.PMID 12952292Read ↗

Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.Semantic proximity Read ↗

Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins.Semantic proximity Read ↗

Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.Semantic proximity Read ↗

Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.Semantic proximity Read ↗

In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiformeSemantic proximity Read ↗

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in GlioblastomaSemantic proximity Read ↗

Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy*Semantic proximity Read ↗

Novel anti-brain tumor cytotoxins specific for cancer cells.Semantic proximity Read ↗

IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic ImplicationsSemantic proximity Read ↗

Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.Semantic proximity Read ↗

Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T CellsSemantic proximity Read ↗

Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.